Market Overview
| Study Period | 2022 - 2031 |
|---|---|
| Forecast Data Period | 2026 - 2031 |
| Base Year Market Size (2025) | USD 4.74 Billion |
| Market Size (2026) | USD 4.97 Billion |
| Market Size (2031) | USD 6.31 Billion |
| Growth Rate (2026 - 2031) | 4.89% CAGR |
| Market Concentration | Medium |
Major Players *Disclaimer: Major Players sorted in no particular order Image © Â鶹ÊÓƵ. Reuse requires attribution under CC BY 4.0. | |
Middle East And Africa In-Vitro Diagnostics Market Analysis by Â鶹ÊÓƵ
The Middle East and Africa In-Vitro Diagnostics Market size was valued at USD 4.74 billion in 2025 and estimated to grow from USD 4.97 billion in 2026 to reach USD 6.31 billion by 2031, at a CAGR of 4.89% during the forecast period (2026-2031).
The COVID-19 pandemic had a significant impact on the in-vitro diagnostics market since there was an increasing demand for IVD kits and reagents for the rapid and accurate diagnosis of SARS-CoV-2 virus infection among the regional population. As per the 2022 report from the United Nations, with the help of several initiatives, including the establishment of the Regional Centre of Excellence for Genomic Surveillance and Bioinformatics in South Africa in collaboration with the SANBI at the University of Western Cape, the WHO increased the number of laboratories able to detect COVID-19 from two to more than 900. WHO also supported genetic sequencing efforts in Africa. In comparison to a year ago, these efforts resulted in more than 7,500 samples in the southern African region, and the amount of sequencing data on the continent increased by more than 54%. The efforts implemented by the government and related resources stimulated the market growth for in-vitro diagnostics in the studied region amid the pandemic. However, as per the analysis, the demand for IVD products may observe a slight decline post pandemic phase owing to a reduction in the number of infected patients and a surge in the vaccination rate across the region.
The major driving factor linked to the growth of the IVD industry in the region is the high burden of chronic diseases, especially infectious diseases, diabetes, and cancers. The Middle East and Africa region is majorly affected due to the burden of chronic diseases. As per the 2021 report from the International Diabetes Federation (IDF), 24 million adults (20-79) are living with diabetes in the IDF Africa Region. This number is estimated to increase to 33 million by 2030 and 55 million by 2045. As per the same source, 73 million adults (20-79) were living with diabetes in the IDF Middle East and North Africa region in 2021. This number is estimated to increase to 95 million by 2030 and 136 million by 2045. The prime factor responsible for this rising burden is the lack of a proper healthcare system across African countries and low awareness about novel disease diagnosis techniques. As per the 2022 review report from UNAIDS, law reform in Angola enabled the country to make use of funds from the Global Fund to combat AIDS, tuberculosis, and malaria to reach young members of critical populations by making it easier for more young people to obtain HIV testing services.
Thus, due to this rise in chronic diseases, the Middle East & Africa In-Vitro Diagnostics market is expected to witness growth over the analysis period. However, stringent regulations associated with the products may restrain the market's growth.
Note: Market size and forecast figures in this report are generated using Â鶹ÊÓƵ’s proprietary estimation framework, updated with the latest available data and insights as of 2026.
Middle East And Africa In-Vitro Diagnostics Market Trends and Insights
Diabetes Segment is Expected to Register High CAGR in the Application Segment
During the forecast period, the diabetes segment is expected to witness healthy growth. Factors such as the growing burden of diabetes, the increasing diagnosis of diabetes, and rising technological advancements in the field of diabetes are the main growth drivers of this segment.
For instance, as per the 2021 report from the African Union Development Agency (AUDA-NEPAD), the African High-Level Panel on Innovation and Emerging Technology (APET) was urging African nations to implement medical management technologies to enhance diabetic healthcare and lessen the burden of the condition. The strain of frequent hospital visits was lessened by the availability of more convenient and accessible healthcare solutions, which were supported by medical management technologies. Furthermore, according to the IDF Diabetes Atlas, 10th edition, published in 2021, an estimated 24 million adults aged 20-79 years were living with diabetes in the IDF Africa region, representing a regional prevalence of 4.5%. Moreover, 54% of people living with diabetes in the region are undiagnosed, the highest proportion of all IDF regions.
The IDF estimates that the increase in diabetes will be 33 million by 2030 and 55 million by 2045. This raises massive healthcare concerns, as all African countries are already struggling to cope with the diabetes burden. However, the WHO reports that diabetes in the region is a serious, chronic, and costly disease that is estimated to rise to 23.9 million cases by 2030.
Hence, the rising prevalence of the disease is expected to drive the growth of the diabetes segment over the forecast period.
GCC Region is Expected to Witness Growth Over The Forecast Period
The GCC in-vitro diagnostics market is expected to grow over the analysis period owing to the growing burden of chronic diseases and increasing healthcare expenditure, which is actively affecting the growth of the market.
The Kingdom of Saudi Arabia made a USD 150 million donations to Gavi, the Vaccine Alliance, in April 2020 to help in the organization's response to the COVID-19 pandemic. The funding was part of a USD 500 million package from the Kingdom of Saudi Arabia to support response to emergencies and preparedness efforts, the deployment of innovative diagnostics, treatments, and vaccinations, and the maintenance of adequate supplies of protective equipment for medical personnel. The government's actions during the pandemic were anticipated to boost the market growth.
Additionally, the COVID-19 pandemic in the GCC region helped the in-vitro diagnostics market grow. For instance, according to a study published in the Cardiovascular Diabetology Journal in December 2020, diabetes mellitus (DM) was the most common comorbidity among COVID-19-positive patients, with prevalence rates of 68.3%, hypertension of 42.6%, and obesity of 42.2%. Patients with COVID-19 who were hospitalized at King Khaled University Hospital (KKUH), Riyadh, Saudi Arabia, had a high prevalence of DM. The demand for in-vitro diagnostics among the patient population was increased by the high prevalence of COVID-19 patients and diabetes mellitus patients.
Moreover, in July 2022, Saudi Arabia's Arabian International Healthcare Holding Company, TIBBIYAH, commenced a new joint venture (JV) with the Swiss company Unilabs Diagnostics AB. Likewise, in April 2022, the United Arab Emirates Sheikh Shakhbout Medical City (SSMC) became one of the first hospitals in the Middle East to launch a prominent point-of-care tool for antimicrobial management.
Therefore, owing to the aforementioned factors, it is anticipated that the studied market will witness growth over the analysis period.
Regulatory Landscape
Regulatory oversight for in-vitro diagnostics (IVDs) across the Middle East and Africa remains fragmented, with country-specific pathways and uneven maturity of national systems. In the UAE, Federal Decree-Law No. 38 of 2024 (effective January 2, 2025) established the Emirates Drug Establishment (EDE) as the regulator for medical products including IVDs, shifting key responsibilities from MOHAP and reinforcing a more centralized market authorization framework.
In Saudi Arabia, the Saudi Food and Drug Authority (SFDA) continues to tighten device-specific requirements. This includes formal guidance for laboratory developed tests through MDS-G022 v2.0 (issued May 18, 2025) and companion diagnostics guidance via MDS-G026 (issued March 18, 2025), which ties evidence expectations to coordinated drug-device review. On the Africa side, WHO reporting notes that while most countries have an authority covering medical devices and IVDs, only a smaller subset has a full hierarchy of legislation and detailed guidance (for example, Ethiopia, Nigeria, South Africa, and Tanzania). This sustains reliance on reference approvals in some markets and adds compliance workload for region-wide launches.
Competitive Landscape
The Middle East and Africa In-Vitro Diagnostics market is competitive and consists of several major players. In terms of market share, a few of the major players currently dominate the market in the GCC. Some of the major players in the market are Abbott Laboratories, BioMerieux SA, Sysmex Corporation, F. Hoffmann-La Roche AG, and Becton, Dickinson, and Company, among others. The companies mostly monitor distribution via their branch offices or distributors operating at the domestic and international levels.
Middle East And Africa In-Vitro Diagnostics Industry Leaders
Abbott Laboratories
F. Hoffmann-La Roche AG
Becton, Dickinson and Company
Sysmex Corporation
BioMerieux SA
- *Disclaimer: Major Players sorted in no particular order
Market Opportunities and Future Outlook
Ongoing localization and regional hub buildouts across Nigeria, Egypt, and the Gulf create openings for suppliers that can support technology transfer, local content, and workforce training alongside instruments and reagents. In June 2026, Abbott partnered with AfriMedical Manufacturing and Supplies Limited to localize production of rapid diagnostic technology in Nigeria, including the Determine Antenatal Care (ANC) Panel, which targets import dependence while matching public health screening needs. In Egypt, Tatweer Medical Industries began a multi-year USD 100 million expansion program in July 2026 at its Badr City factory in partnership with Mindray, aimed at manufacturing advanced diagnostic equipment for domestic use and export to African markets, signaling growing regional capacity for IVD-adjacent diagnostics manufacturing and servicing.
A parallel opportunity is the deployment of advanced and connected diagnostics in GCC health systems, where providers and laboratory networks are modernizing core lab capability and data integration. Roche rolled out cobas Mass Spec technology in Saudi Arabia and the UAE in June 2026 and announced subsequent deployments for Jordan and Qatar, supporting higher-complexity testing beyond routine immunoassay and chemistry in select sites. At the same time, regulatory tightening, including SFDA companion diagnostics guidance (MDS-G026, March 2025) and the UAE shift to EDE (effective January 2025), increases the need for in-country regulatory expertise, local clinical evidence planning, and quality systems support for manufacturers expanding menus across molecular diagnostics, oncology-related testing, and point-of-care platforms.
Recent Industry Developments
- June 2026: Abbott partnered with AfriMedical Manufacturing and Supplies Limited to localize production of rapid diagnostic technology in Nigeria, including the integrated Determine Antenatal Care (ANC) Panel, at a facility in Ogun State. The effort supports local supply resilience and gives Abbott a manufacturing-led base to scale access to rapid testing across West Africa.
- June 2025: The Department of Health - Abu Dhabi and Abbott announced a partnership focused on local manufacturing of pharmaceuticals and the development of digital health solutions. While not limited to diagnostics, the collaboration strengthens Abbott's localization footprint in a key GCC hub and supports broader market access discussions with government stakeholders and health systems.
- March 2024: Roche expanded regional collaboration efforts aimed at laboratory modernization through partnerships with healthcare providers and laboratory networks across the Middle East and Africa. These tie-ups reflect an ongoing shift toward integrated diagnostic infrastructure, where technology deployment is paired with workflow digitization and service support.
Research Methodology Framework and Report Scope
Market Definition and Coverage
For this study, the Middle East and Africa in vitro diagnostics (IVD) market is defined as revenues earned from lab and near-patient tests that analyze human samples outside the body, including the related instruments and consumables sold to run those tests.
Scope exclusions: Excludes imaging diagnostics, purely clinical services that do not involve an IVD product sale, and non-human testing (such as veterinary and food testing).
Segmentation Overview
- By Technique
- Histochemistry
- Molecular Diagnostics
- Hematology
- Self-blood Glucose Testing
- Immunochemistry
- Other Techniques
- By Product
- Instrument
- Reagent
- Other Products
- By Usability
- Disposable IVD Device
- Reusable IVD Device
- By Application
- Infectious Disease
- Diabetes
- Cancer/Oncology
- Cardiology
- Autoimmune Disease
- Other Applications
- By End User
- Diagnostic Laboratories
- Hospitals and Clinics
- Other End Users (Academic and Medical School)
- By Diagnostic Approach
- Point-of-Care Diagnostics
- Centralized Laboratory-based Diagnostics
- Geography
- GCC
- South Africa
- Rest of Middle East & Africa
Data Sources, Market Sizing, and Validation
Desk Research
Desk work starts by mapping disease and testing demand signals across the region, and then matching those signals with how laboratories and hospitals procure IVD products. We relied on public health and statistics sources such as World Health Organization dashboards, World Bank indicators, national health ministry publications, and selected country statistical agencies to understand testing volumes and care access.
We also reviewed customs and trade reporting (where available) to sense-check cross-border flow of reagents and instruments, followed by medical laboratory association updates and peer-reviewed papers that describe typical test utilization and guideline changes. Company annual reports, investor presentations, and reputable press were used to validate product mix shifts and pricing direction, and a paid subscription for company financials and patent screening helped with product pipeline timing. These examples are not exhaustive, and other public sources were also used for collection, validation, and clarification during the work.
Primary Interviews and Surveys
Primary discussions were completed with a mix of IVD manufacturers, regional distributors, procurement teams, and lab operations leaders. The goal was to stress-test what we saw in the desk work and to close gaps around pricing, placement models, and utilization rates by setting. Since this is a multi-country market, we balanced responses across major Middle East and African demand centers, then used follow-up questions when assumptions did not align with observed health spending and testing patterns.
Distribution of primary research fieldwork respondents
| Company type | Respondent position | Region |
|---|---|---|
| Top tier: 29% | CXOs: 12% | |
| Mid tier: 57% | Functional/Unit leaders: 31% | |
| Smaller Players: 14% | Managers: 57% |
Market-Sizing & Forecasting
Sizing is built using a top-down demand pool approach where population, disease prevalence, screening or monitoring practices, and lab testing rates are used to reconstruct likely test volume by major category, which is then converted into revenue using practical price ranges. To keep the calculations grounded, we corroborate results using selective bottom-up checks, such as rolling up sampled supplier and channel revenues for key countries, and then scaling cautiously where coverage is thinner.
Inputs that typically move the model include direction of public and private healthcare spend, laboratory network expansion, adoption of rapid tests versus routine lab methods, reagent-to-instrument pull-through ratios, and currency movements that affect imported product pricing. For markets where direct utilization data is limited, we handle gaps by using proxy indicators (like hospital admissions and outpatient visits) and then validating the implied per-capita testing with interview feedback. Forecasts are produced using scenario analysis, with variables such as testing policy, funding cycles, and expected price progression adjusted to reflect the consensus view heard from field experts.
Data Validation & Update Cycle
Checks are done at multiple points so the final totals align with real-world signals, not just a single dataset. Outputs are compared against independent indicators such as healthcare spending trends, import intensity for key product types, and the implied testing rate per 1,000 population for large countries, and then large variances are investigated before sign-off.
A second analyst review is completed to confirm calculations, unit handling, and currency conversion timing, and follow-up outreach is triggered when an assumption creates an outlier versus known procurement or utilization patterns. Reports are refreshed annually, and interim updates are added when material events occur, such as policy shifts, large tender activity, or major pricing changes. Before delivery, the latest public releases are rechecked so clients receive an updated view.
Â鶹ÊÓƵ's Vitro Diagnostics Middle East and Africa Market Size Compared With Other Published Estimates
Published market values for MEA IVD rarely match perfectly, even when the geography label looks the same, because the counted items and the timing of assumptions can differ. Differences usually come from what gets included as IVD revenue, how pricing is handled for imported products, and whether the estimate is built from test demand signals or from supplier sales proxies.
Services-only lab revenue and broader pathology service billing sit outside Â鶹ÊÓƵ's scope here, which is one reason some published totals can look lower or higher depending on whether those line items were mixed in or separated. Other gaps often come from using a single base year exchange rate for all countries, keeping prices flat through the forecast, or applying one regional growth rate without rechecking country-level testing policy and procurement cadence.
Benchmark comparison
| Source | Market Size | Gaps in Research Methodology |
|---|---|---|
| Â鶹ÊÓƵ | USD 4.74 B (2025) | |
| Industry Databook A | USD 2.54 B (2024) | Uses a different starting year and appears to emphasize a narrower revenue capture tied to reported sales by product groups, which can undercount parts of routine lab testing that are procured through bundled channels. |
| Regional Research House B | USD 2.62 B (2025) | Applies a lower growth path and may treat pricing progression more conservatively for imported reagents and instruments, and it is less clear how country-level testing utilization checks were used to validate implied volumes. |
The comparison mainly shows that year alignment and what is counted as IVD revenue explain much of the spread, followed by pricing and currency treatment across diverse MEA markets. By keeping inputs traceable to testing demand signals and then cross-checking with channel realities, we end up with a number that is easier to replicate and audit when assumptions need to be updated.
Key Questions Answered in the Report
How big is the Middle East and Africa In-Vitro Diagnostics Market?
The Middle East and Africa In-Vitro Diagnostics Market size is expected to reach USD 4.97 billion in 2026 and grow at a CAGR of 4.89% to reach USD 6.31 billion by 2031.
What is the current Middle East and Africa In-Vitro Diagnostics Market size?
In 2026, the Middle East and Africa In-Vitro Diagnostics Market size is expected to reach USD 4.97 billion.
Who are the key players in Middle East and Africa In-Vitro Diagnostics Market?
Abbott Laboratories, F. Hoffmann-La Roche AG, Becton, Dickinson and Company, Sysmex Corporation and BioMerieux SA are the major companies operating in the Middle East and Africa In-Vitro Diagnostics Market.
What years does this Middle East and Africa In-Vitro Diagnostics Market cover, and what was the market size in 2025?
In 2025, the Middle East and Africa In-Vitro Diagnostics Market size was estimated at USD 4.97 billion. The report covers the Middle East and Africa In-Vitro Diagnostics Market historical market size for years: 2021, 2022, 2023 and 2024. The report also forecasts the Middle East and Africa In-Vitro Diagnostics Market size for years: 2026, 2027, 2028, 2029, 2030 and 2031.
Page last updated on:
